Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

Maurizio Genuardi, Antonio Palumbo, Alessandra Larocca, Mariella Genuardi, Katarzyna Kotwica, Francesca Gay, Davide Rossi, Giulia Benevolo, Valeria Magarotto, Federica Cavallo, Sara Bringhen, Cecilia Rus, Luciano Masini, Massimo Lacobelli, Gianluca Gaidano, Constantine Mitsiades, Kenneth Anderson, Mario Boccadoro, Paul Richardson

Risultato della ricerca: Contributo in rivistaArticolo in rivista

33 Citazioni (Scopus)

Abstract

Background Defibrotide is a novel orally bioavailable polydisperse oligonucleotide with anti-thrombotic and anti-adhesive effects. In SCID/NOD mice, defibrotide showed activity in human myeloma xenografts. This phase I/II study was conducted to identify the most appropriate dose of defibrotide in combination with melphalan, prednisone and thalidomide in patients with relapsed and relapsed/refractory multiple myeloma, and to determine its safety and tolerability as part of this regimen. Design and Methods This was a phase I/II, multicenter, dose-escalating, non-comparative, open label study. Oral melphalan was administered at a dose of 0.25 mg/kg on days 1-4, prednisone at a dose of 1.5 mg/kg also on days 1-4 and thalidomide at a dose of 50-100 mg/day continuously. Defibrotide was administered orally at three dose-levels: 2.4, 4.8 or 7.2 g on days 1-4 and 1.6, 3.2, or 4.8 g on days 5-35.3 Results Twenty-four patients with relapsed/refractory multiple myeloma were enrolled. No dose-limiting toxicity was observed. In all patients, the complete response plus very good partial response rate was 9%, and the partial response rate was 43%. The 1-year progression-free survival and 1-year overall survival rates were 34% and 90%, respectively. The most frequent grade 3-4 adverse events included neutropenia, thrombocytopenia, anemia and fatigue. Deep vein thrombosis was reported in only one patient. Conclusions This combination of melphalan, prednisone and thalidomide together with defibrotide showed anti-tumor activity with a favorable tolerability. The maximum tolerated dose of defibrotide was identified as 7.2 g p.o. on days 1-4 followed by 4.8 g p.o. on days 5-35. Further trials are needed to confirm the role of this regimen and to evaluate the combination of defibrotide with new drugs (ClinicalTrials.gov Identifier: NCT00406978).
Lingua originaleEnglish
pagine (da-a)1144-1149
Numero di pagine6
RivistaHaematologica
Volume95
DOI
Stato di pubblicazionePubblicato - 2010

Keywords

  • BORTEZOMIB
  • CHEMOTHERAPY
  • COMBINATION
  • ELDERLY-PATIENTS
  • ORAL MELPHALAN
  • PLUS THALIDOMIDE
  • RANDOMIZED CONTROLLED-TRIAL

Fingerprint Entra nei temi di ricerca di 'Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial'. Insieme formano una fingerprint unica.

Cita questo